文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗治疗黑色素瘤的毒性效应与治疗失败时间评估

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
PubMed 文献 · JAMA Oncol · 2018-01-01

该前瞻性队列纳入64例晚期或不可切除黑色素瘤成人患者,接受纳武利尤单抗联合伊匹木单抗治疗。91%患者出现临床显著免疫相关不良事件,中位2次/人,72%需全身激素,50%曾急诊就诊,36%因免疫相关不良事件住院。多数患者未能耐受4剂联合治疗,但4剂可能并非临床获益所必需。

要点

  • 91%患者出现临床显著免疫相关不良事件,中位2次/人,72%需全身激素。
  • 50%患者因免疫相关不良事件急诊就诊,36%需住院,25%需英夫利西单抗或霉酚酸酯。
  • 仅39%完成4剂联合治疗,48%未接受维持抗PD-1治疗,80%停药因毒性。

核心结论

  • 观察到91%的临床显著免疫相关不良事件发生率,导致频繁急诊就诊、住院和全身免疫抑制。
  • 免疫肿瘤学试验应常规报告这些指标。
  • 多数患者不能耐受4剂纳武利尤单抗联合伊匹木单抗;然而,4剂可能并非临床获益所必需。

研究设计与样本

  • 前瞻性队列研究,在单一三级癌症中心纳入64例晚期或不可切除黑色素瘤成人患者,参加纳武利尤单抗联合伊匹木单抗扩展可及项目,时间为2014年12月至2016年1月。

主要发现

  • 64例患者中男女性别比1:1,中位年龄56岁(范围22-82岁);25例(39%)接受全部4剂联合治疗,31例(48%)未接受维持抗PD-1治疗。
  • 停药患者中31例(80%)因毒性停药。
  • 58例(91%)出现临床显著免疫相关不良事件(中位2次/人),46例(72%)需全身激素,16例(25%)因激素难治性免疫相关不良事件需英夫利西单抗或霉酚酸酯。
  • 7例(11%)出现高血糖,32例(50%)因免疫相关不良事件急诊就诊,23例(36%)因免疫相关不良事件住院。
  • 31例因毒性提前停止联合治疗的患者中,4例(13%)在末次治疗后超过16周出现新的临床显著免疫相关不良事件。

关键数值与推荐

  • 临床显著免疫相关不良事件定义为CTCAE 2级或以上或任何需全身激素的免疫相关不良事件。
  • 治疗失败时间定义为从开始治疗至临床进展、新的局部定向或全身治疗(抗PD-1单药除外)或死亡的最早时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which may underestimate incidence of clinically significant immune-related adverse events (AEs). OBJECTIVE: To describe detailed toxic effects and time to treatment failure of patients with melanoma treated with nivo + ipi in a prospective cohort. DESIGN, SETTING, AND PARTICIPANTS: A cohort of 64 adults with advanced or unresectable melanoma were examined at a single tertiary cancer and enrolled in an expanded access program of nivo + ipi conducted from December 2014 to January 2016. INTERVENTIONS: Intravenous nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) administered every 3 weeks for up to 4 doses, followed by nivolumab (3 mg/kg) every 2 weeks or pembrolizumab (2 mg/kg) every 3 weeks until unacceptable toxic effects, disease progression, or complete response. MAIN OUTCOMES AND MEASURES: Clinically significant immune-related AEs were defined as CTCAE grade 2 or higher or any immune-related AEs requiring systemic steroids. Time to treatment failure was defined as the interval between initiating therapy and the earliest of clinical progression, new locally directed or systemic treatment other than anti-programmed cell death 1 protein (anti-PD-1) monotherapy, or death. RESULTS: Overall 64 adults with advanced or unresectable melanoma were enrolled (male to female ratio, 1:1; median [range] age, 56 [22-82] years); 25 patients (39%) received all 4 doses of nivo + ipi, and 31 patients (48%) received no maintenance anti-PD-1 therapy. Most who discontinued treatment (n = 31 [80%]) stopped because of toxic effects. Among those patients who were progression free at 12 weeks, time to treatment failure was similar between those who did or did not modify therapy for toxic effects. Fifty-eight patients (91%) had a clinically significant immune-related AE (median, 2/patient), and 46 patients (72%) required systemic steroids. Infliximab or mycophenolate was required in 16 patients (25%) for steroid-refractory immune-related AEs. Seven patients (11%) developed hyperglycemia, 32 patients (50%) had an emergency department visit, and 23 patients (36%) required a hospital admission related to an immune-related AE. Four of 31 patients (13%) who stopped combination therapy early for toxic effects developed a new, clinically significant immune-related AE more than 16 weeks after the last treatment. CONCLUSIONS AND RELEVANCE: We observed a 91% incidence of clinically significant immune-related AEs leading to frequent emergency department visits, hospitalizations, and systemic immunosuppression. Immuno-oncology trials should routinely report these metrics. Most patients do not tolerate 4 doses of nivo + ipi; however, 4 doses may not be required for clinical benefit.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncol. 2018. PMID: 28817755. doi:10.1001/jamaoncol.2017.2391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。